Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression

Ng, Chee H.; Sarris, Jerome; Singh, Ajeet; Bousman, Chad A.; Byron, Keith; Peh, Lai Huat; Smith, Deidre J.; Tan, Chay Hoon; Schweitzer, Isaac

doi:10.1002/hup.2340

Cited by 37 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HTTLPR S/S genotype carriers had a reduced antidepressant effect compared to those carrying the L allele. This finding is consistent with our previous work showing that L/L allele for HTTLPR is associated with a robust treatment response to escitalopram in Caucasian subjects [10]. However this was in contrast to the finding by Proft et al [4], which showed a significant association between SLC6A4 genotype (l A l A ) and poor response to venlafaxine.…”

supporting

confidence: 92%

A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder

Bousman

Smith

et al. 2016

Pharmacopsychiatry

View full text Add to dashboard Cite

No studies to date have evaluated and genetic polymorphisms influencing antidepressant response to desvenlafaxine. We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine. Results revealed that homozygotes for the HTTLPR allele showed a 33% HDRS reduction compared to a 58% reduction for L allele carriers (p=0.037). No results survived adjustments for covariates or multiple comparisons. While these results need to be interpreted cautiously, they provide preliminary support for the HTTLPR polymorphism as potential modifier of desvenlafaxine efficacy.

show abstract

supporting

confidence: 92%

A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder

Bousman

Smith

et al. 2016

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…However, the study focused on sertraline metabolism in relation to CYP2C19, failed to identify any significant changes [44]. Furthermore, the same 8 weeks' study previously described for CYP2D6, found contrasting differences between CYP2C19 poor/intermediate and CYP2C19 extensive/ultra-rapid metabolizer after administration of escitalopram and venlafaxine [39].…”

Section: Cyp2d6mentioning

confidence: 93%

Blood biomarkers and treatment response in major depression

Mora

Zonca

Riva

et al. 2018

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Millions of people worldwide suffer from depression, but despite advances in pharmacological therapies, many patients do not experience symptomatic remission or treatment response, even after treatments with several medications. As such, there is an urgent need to identify biomarkers that can not only predict the treatment response but also allow a rational selection of optimal therapy for each patient. Areas covered: This review examines the recent findings, coming from different 'omic sciences,' in human blood-based biomarkers associated with antidepressant treatment response with particular attention on genetic/epigenetic and biochemical biomarkers. Specific emphasis will be placed on key molecules related to neuroplasticity and inflammation because of their involvement in the pathophysiology of depression and antidepressant response. Expert commentary: Biomarker identification is still an ongoing work. Indeed, to date, no biomarkers have sufficiently proven specificity, sensitivity, and reproducibility to be used in the clinical setting. However, 'omic' approaches hold great promise in identifying multiple features for predicting antidepressant response, making a personalized treatment strategy possible for each patient, and thereby assist with quick and efficacious responsiveness. It is thus necessary that future studies take an integrative approach that includes clinical assessment, environment influences, and molecular and biological biomarkers.

show abstract

“…A metaanalysis suggested that the long allele of 5-HTTLPR may be a predictor of antidepressant response in Caucasians, but not Asians [54]. Two recent studies also showed that the l/l allele for 5-HTTLPR was associated with a better treatment response to escitalopram, but in Caucasians only [55,56]. In some Asian studies, favorable treatment outcome was associated with the short allele [57,58].…”

Section: The Serotonin Transporter Gene-linked Polymorphic Regionmentioning

confidence: 95%

Advances in Biomarkers of Major Depressive Disorder

Huang

Lin

2015

Advances in Clinical Chemistry

View full text Add to dashboard Cite

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression

Abstract: Ethnicity may have differential effects on the 5-HTTLPR genotype-efficacy relationship. Results suggest that l/l allele for 5-HTTLPR is associated with a robust treatment response to ESC in Caucasian subjects only.

Cited by 37 publications

References 20 publications

A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder

A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder

Blood biomarkers and treatment response in major depression

Advances in Biomarkers of Major Depressive Disorder

Contact Info

Product

Resources

About